The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2018 | Understanding how genetic mutations affect outcome in CLL
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, William Wierda, MD, PhD, of the MD Anderson Cancer Center, Houston, TX, discusses his group’s 29-gene panel for genetically screening chronic lymphocytic leukemia (CLL) patients. He demonstrates how genetic data can be compared to treatment outcome, in order to illuminate the relationship between the CLL mutational landscape and treatment efficacy.
